c-RET
The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
Products for c-RET
- Cat.No. Nom du produit Informations
- GC16362 AD57 (hydrochloride) polypharmacological cancer therapeutic that inhibits RET.
- GC16391 Amuvatinib (MP-470, HPK 56) A multi-targeted RTK inhibitor
- GC15217 Danusertib (PHA-739358) A pan-Aurora kinase and Abl inhibitor
- GC14606 Regorafenib hydrochloride A multi-kinase inhibitor
- GC14534 Regorafenib monohydrate A multi-kinase inhibitor
- GC13194 RPI-1 RPI-1 est un inhibiteur spécifique de la 2-indolinone Ret tyrosine kinase disponible par voie orale. RPI-1 inhibe la prolifération, la phosphorylation de la tyrosine Ret, l'expression de la protéine Ret et l'activation de PLCgamma, ERK et AKT dans les cellules TT du carcinome médullaire de la thyroÏde humaine. Activité antitumorale.
-
GC15307
SU5416
A tyrosine kinase inhibitor
- GC10035 TG101209 An inhibitor of JAK2, FLT3, RET, and JAK3